Abstract:

In a recent issue of Hepatology, Lei et al.⁽¹⁾ conducted a multicenter retrospective cohort study that included 5,771 adult patients with coronavirus disease 2019 (COVID-19) pneumonia in Hubei Province. The purpose of the study was to evaluate the relationships between liver injury indicators (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and total bilirubin [TBIL]) and mortality in COVID-19 patients. The authors considered the possibility that elevated liver injury indicators, particularly AST, are strongly associated with mortality risk. However, the association between liver injury indicators and mortality in COVID-19 patients should be interpreted cautiously in light of the following issues.

Open in

PUBMED | DOI | Google Scholar | Wikipedia

Relations:

Content

Diseases

(1)

Drugs

(1)

Chemicals

(2)

Organisms

(1)

Letter to the Editors: Additional Factors to Consider When Studying Liver Injury Indicators and Mortality in COVID‐19 Patients

Yanqing Liu

^{Department of Clinical Laboratory, Ningbo First Hospital, Ningbo Zhejiang, China,}

Yanqing Liu, Email: moc.621@9891gniqnayuil.

^{Corresponding author.}

^{Address correspondence and reprint requests to}: Yanqing Liu, M.D.
Department of Clinical Laboratory, Ningbo First Hospital, 59 Liuting Street, Ningbo, 315010 Zhejiang, China
E‐mail: moc.621@9891gniqnayuil,

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.

Learn More